Immunophotonics
Latest round
- Series B
Last raised
- Apr 2022
Total raised
- $24M
Investors
- 10
About Immunophotonics
Based in Missouri, US, and founded in 2012, Immunophotonics, Inc. provides a carbohydrate polymer that can turn cancer hypnosis into the removal of tumors. As of 2023, the company is headed by its CEO Lu Alleruzzo, who co-founded the firm along with Thomas Hode. The company offers situ autologous (therapeutic) cancer vaccines (inCVAX) for the treatment of metastatic cancers. Following a tumor ablation, the company's chemical is administered intratumorally, utilizing the full spectrum of tumor-associated neoantigens that are present in situ for the immune system following ablation-based immunogenic cell death.
Who invested in Immunophotonics
10 investors across 5 rounds
See all investors in Immunophotonics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immunophotonics
Who invested in Immunophotonics?
Immunophotonics has 10 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immunophotonics raised?
Immunophotonics has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Immunophotonics last raise money?
Immunophotonics's most recent round on record is a Series B, in Apr 2022.
What does Immunophotonics do?
Based in Missouri, US, and founded in 2012, Immunophotonics, Inc.
Where is Immunophotonics headquartered?
Immunophotonics is headquartered in St. Louis, US.
Which VCs invest in companies like Immunophotonics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Immunophotonics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Immunophotonics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.